Collegium Pharmaceutical - COLL Stock Forecast, Price & News

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Collegium Pharmaceutical in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" COLL shares.
View COLL analyst ratings or view top-rated stocks.

4 equities research analysts have issued 12 month price objectives for Collegium Pharmaceutical's stock. Their COLL share price forecasts range from $26.00 to $42.00. On average, they predict the company's share price to reach $33.00 in the next twelve months. This suggests a possible upside of 20.5% from the stock's current price.
View analysts price targets for COLL or view top-rated stocks among Wall Street analysts.

Collegium Pharmaceutical's stock was trading at $23.20 at the start of the year. Since then, COLL stock has increased by 18.0% and is now trading at $27.38.
View the best growth stocks for 2023 here.

Collegium Pharmaceutical saw a increase in short interest in January. As of January 15th, there was short interest totaling 3,970,000 shares, an increase of 8.5% from the December 31st total of 3,660,000 shares. Based on an average daily volume of 306,100 shares, the days-to-cover ratio is currently 13.0 days. Approximately 12.3% of the shares of the stock are sold short.
View Collegium Pharmaceutical's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our COLL earnings forecast.

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) released its quarterly earnings data on Thursday, November, 3rd. The specialty pharmaceutical company reported $0.96 EPS for the quarter, missing analysts' consensus estimates of $1.04 by $0.08. The specialty pharmaceutical company earned $127.01 million during the quarter, compared to the consensus estimate of $123.65 million. Collegium Pharmaceutical had a negative net margin of 11.84% and a positive trailing twelve-month return on equity of 12.66%.

Collegium Pharmaceutical updated its FY 2023 earnings guidance on Wednesday, January, 4th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $565.00 million-$580.00 million, compared to the consensus revenue estimate of $550.58 million.

6 employees have rated Collegium Pharmaceutical Chief Executive Officer Joseph Ciaffoni on Glassdoor.com. Joseph Ciaffoni has an approval rating of 68% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Collegium Pharmaceutical investors own include Galapagos (GLPG), NVIDIA (NVDA), AbbVie (ABBV), Advanced Micro Devices (AMD), Cara Therapeutics (CARA), Pfizer (PFE), Bausch Health Companies (BHC), Gilead Sciences (GILD) and GW Pharmaceuticals (GWPH).

(COLL) raised $75 million in an initial public offering on Thursday, May 7th 2015. The company issued 5,800,000 shares at $12.00-$14.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and Wells Fargo Securities and Needham & Company were co-managers.

Collegium Pharmaceutical trades on the NASDAQ under the ticker symbol "COLL."

Collegium Pharmaceutical's stock is owned by a number of institutional and retail investors. Top institutional investors include Peregrine Capital Management LLC (1.61%), Assenagon Asset Management S.A. (0.40%), Exchange Traded Concepts LLC (0.23%), Acorn Financial Advisory Services Inc. ADV (0.16%), Values First Advisors Inc. (0.14%) and New York State Common Retirement Fund (0.08%). Insiders that own company stock include Alison B Fleming, Colleen Tupper, Joseph Ciaffoni, Michael Thomas Heffernan, Scott Dreyer and Shirley R Kuhlmann.
View institutional ownership trends.

Shares of COLL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of COLL stock can currently be purchased for approximately $27.38.

Collegium Pharmaceutical (NASDAQ:COLL) has a market capitalization of $919.15 million and generates $276.87 million in revenue each year. The specialty pharmaceutical company earns $71.52 million in net income (profit) each year or ($1.26) on an earnings per share basis.

The company employs 152 workers across the globe.

Collegium Pharmaceutical's mailing address is 100 Technology Center Drive, Stoughton MA, 02072. The official website for the company is www.collegiumpharma.com. The specialty pharmaceutical company can be reached via phone at (781) 713-3699 or via email at info@collegiumpharma.com.